Summit Therapeutics Inc.
SMMT
Rank in Stocks
#1666
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Share Price
$16.14
Market Cap
$12.87B
Change (1 day)
3.65%
Change (1 year)
-19.47%
Country
US
Trade Summit Therapeutics Inc. (SMMT)
Category
Healthcare
Stock split history for Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. stock (symbol: SMMT) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One SMMT share bought prior to Oct 20, 2026 would equal to 0 SMMT shares today.
The most recent stock split occurred on Oct 20, 2026.
One SMMT share bought prior to Oct 20, 2026 would equal to 0 SMMT shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
